3 Microcap Stocks with Pending FDA Approvals

Spotlight Growth - Penny Stocks, Small Cap Stocks, Micro-Cap and Micro Cap Stocks, Stock Exchange, NASDAQ, Crypto, BitCoin, DogeCoin, Ai, Artificial Intelligence, Chat GPT, OpenAi, Open Ai, ASURE Software, Trending, Now, Breaking News, BioTech, Data, Analytics, Technology, Big Tech, Banking, SVB, Bank Closures, Failures, Finance, Stock Market News, WeBull, RobinHood, Reddit Traders, Trading, Investing, Investors, Investment, Investments, Day Trading, Real Estate, VC, Venture Capital, Private Equity, Firm, Firms, OTC Markets, Public, Private, OTCQB, GOOG, APPLE, Shareholders, Stakeholders, Shares, Finance Education, Blog, Articles, Consumer Goods, Pharma, Commodities, Precious Metals, Gold, Silver, Cannabis, CBD, Lithium, Electric Vehicles, Solar, Tesla, Charging, EV, Cloud Computing, Wall Street Bets, Sports Betting, Economy, Economics, IPO, Trade Ideas, Intellectual Property Rights, Private Placement, Crowd Funding, Fundraising, Meta, Metaverse, Web 3, Cyber, Cybersecurity, Cyber Security, Aircraft, VPN, Yahoo Finance, Benzinga, BarChart.

Stocks that receive approval from the FDA for their new drugs can often rocket to new highs. These three microcaps have upcoming PDUFA (Prescription Drug User Fee Act) dates that will impact their underlying stocks.

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) learned earlier this year what it’s like to have the FDA not approve your crown jewel drug. The stock had traded as high as $9.93 last year before dropping to almost $2 on the negative FDA news.

The company now has a new date, and new hope, for it’s once-daily intravenous (IV) eravacycline drug, designed for hard-to-treat urinary tract infections. The FDA is reviewing the drug and has set a tentative date of August 28, 2018 for a decision.

On June 11th the company presented positive data on two trials of the drug that it had conducted. CEO and President of Tetraphase Pharmaceuticals, Guy MacDonald, stated they were “pleased to show that favorable clinical and microbiological responses were observed for eravacycline…” Holders of the stock will be rewarded if these favorable responses carry through to FDA approval.

EyePoint Pharmaceuticals (NASDAQ: EYPT) is developing sustained release products to treat retinal diseases and other eye conditions. The company has a November 5, 2018 PDUFA for it’s Durasert and Durasert micro-insert products.

The Durasert product is already marketed in the U.K, Germany and Portugal, and is awaiting approval in 13 other countries in addition to the United States.

The product is superior to others on the market in that it treats a hard to reach areas of the eye, where for certain conditions, medicine must be delivered on a regular basis.

Instead of eye injections every few months, the Durasert product is inserted and delivers the needed medicine without injections. If EYPT receives FDA approval in November the stock’s investors may be “eyeing” a hefty profit.

Trevena, Inc. (NASDAQ: TRVN) develops pain relievers for moderate-to-severe acute pain, such as that associated with a migraine.

Trevena’s Oliceridine injection has been designated a Breakthrough Therapy by the FDA, and has a PDUFA date of November 2, 2018.

The stock has been range bound this year, trading between $1.50 and $2.30. With the stock trading in the $1.60s, now may be a good time to establish a position.

The company also recently added three experienced marketing and medical affairs members to their staff, perhaps in anticipation of getting an approved drug into patient’s hands.

FDA approval of their product may positively impact one or more of these microcaps in the next few months. Taking a position now may prove to be a prudent investment headed into year-end.

Disclaimer: The author and Spotlight Growth has no positions in any of the stocks mentioned in this article. Nor does either party currently have any relationship, or any other conflicts of interest, with any of the companies mentioned in this article. This content is meant for informational and entertainment purposes only and should not be meant as a recommendation to buy or sell any securities. Please visit a licensed financial representative to determine what investments are right for you.

Article By: Steven Adams

3 Microcap Stocks with Pending FDA Approvals

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

Vision Marine (NASDAQ: VMAR): An Innovative, Revenue-Producing Company Riding the Electric Boating Growth Trend

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

Telcoin (TEL) Continues to Demonstrate Fundamental Progress, Displaying Bullish Technical Setup

Grove Collaborative (NYSE: GROV) Expands Retail Distribution Footprint Into 2,200 Additional Stores

The Metaverse is Exploding in Popularity and Growth

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

Safe-T Group Ltd. (NASDAQ: SFET) to Participate at A.G.P.’s Virtual Emerging Growth Technology Conference on February 4, 2021

Nvidia Announces New Chip Specifically For Ethereum Mining

Sortis Holdings, Inc. (OTC Pink: SOHI) Announces Results for Second Quarter 2020

Medical Marijuana Coming Soon to Virginia

SushiSwap (SUSHI) Appropriates Uniswap’s Liquidity Pool by Preempting Native Token Release

Europe Shows Signs of Warming to SPACs

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)

Vivos Therapeutics (NASDAQ: VVOS) Secures Strategic Alliances to Enhance Clear Aligner Offerings and Bolster Revenue Streams

Shares of Soleno Therapeutics (NASDAQ: SLNO) Surge Over 500% After Its DCCR Candidate Shows Promise in PWS Clinical Trials

Understanding EBITDA and Adjusted EBITDA: A View Into Asure’s (NASDAQ: ASUR) Recent Financial Performance

From Microsoft to Travel Tech: VCI Global’s (NASDAQ: VCIG) Expanding AI Horizons

Singapore’s Leap into the Future of Cell and Gene Therapies

Asure (NASDAQ: ASUR) Completes Capital Raise to Fuel High-Interest Debt Reduction, Craig-Hallum Analyst Praises Move and Estimates Bullish Outcome

Asure (NASDAQ: ASUR) Reports Massive 50% Y/Y Revenue Growth During Q2 2023, Raises $40 Million to Pay Off High-Interest Debt and Fund Acquisitions

Recent News

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Categories

Site Navigation